Drew Barrymore on Perimenopause and HRT: Press Coverage and Public Statements

What Drew Barrymore Has Said About Perimenopause

Drew Barrymore first brought perimenopause into her public conversation during episodes of The Drew Barrymore Show in 2023 and continued through 2024 and into 2025. She described recognizing unfamiliar emotional and physical symptoms in her late 40s, a timeline consistent with the average onset of perimenopause between ages 40 and 44 according to the North American Menopause Society (NAMS) [1].

On-Air Disclosures

During a 2023 segment, Barrymore described feeling "not like myself" and referenced difficulty sleeping, irritability that felt disproportionate to circumstances, and a general sense of cognitive slowness she had not experienced before. She framed these changes as confusing before she connected them to hormonal shifts. These descriptions align closely with the vasomotor and neuropsychiatric symptom clusters documented in the SWAN (Study of Women's Health Across the Nation) longitudinal cohort, which followed 3,302 women through the menopausal transition and found that 60% to 80% experienced vasomotor symptoms while roughly 40% reported depressive episodes during perimenopause [2].

Conversations With Guests and Experts

Barrymore has hosted gynecologists and menopause specialists on her show, asking direct questions about treatment options including hormone therapy, lifestyle modifications, and supplements. In one notable exchange, she asked a guest physician whether HRT was "safe now" given the fear many women carry from the Women's Health Initiative (WHI) headlines of 2002. That question reflects a pattern researchers at Yale documented in a 2013 analysis: an estimated 50% decline in HRT prescriptions followed the initial WHI press release, and prescribing rates have never fully recovered [3].

Social Media and Interview Statements

On Instagram and in print interviews with outlets including People and InStyle, Barrymore has referenced "going through it" with hormonal changes. She has emphasized that talking openly removes stigma. She has not, as of May 2026, named a specific medication, dosage, or prescribing physician in any verified public statement. Any attribution of a specific HRT regimen to Barrymore that appears online should be treated as inference unless sourced to a direct quote.

Why Celebrity Perimenopause Disclosures Matter Clinically

High-profile disclosures shift patient behavior. That is not speculation. A 2024 survey published in Menopause: The Journal of The North American Menopause Society found that 34% of women who initiated a conversation with their physician about perimenopause cited a celebrity or media figure as the prompt [4]. Barrymore's audience skews toward women aged 35 to 54, the exact demographic entering or navigating perimenopause.

The "Permission Effect"

Researchers at the University of Pittsburgh coined the term "permission effect" to describe the phenomenon where a trusted public figure's disclosure lowers the psychological barrier for patients to seek care. The effect is measurable. Following Oprah Winfrey's 2009 discussion of bioidentical hormones, Google Trends data showed a 260% spike in searches for "bioidentical hormone therapy" within 72 hours [5]. Barrymore's disclosures have produced similar, if smaller, search interest surges.

Closing the Treatment Gap

The treatment gap for perimenopause and menopause is wide. According to a 2023 AARP and National Institutes of Health survey, only 1 in 5 women experiencing menopause symptoms discussed treatment options with a healthcare provider [6]. The Endocrine Society's 2022 position statement explicitly recommends that clinicians proactively screen women aged 40 and older for menopausal symptoms and discuss the risk-benefit profile of hormone therapy [7]. Celebrity advocacy does not replace clinical screening, but it creates demand for the conversation.

The Medical Field Barrymore Is Navigating

To evaluate any public figure's statements about HRT, it helps to understand what the evidence actually supports in 2026. The field has shifted substantially since the WHI panic of the early 2000s.

What the WHI Actually Found

The Women's Health Initiative enrolled 27,347 postmenopausal women aged 50 to 79 and randomized them to conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) or placebo. The estrogen-plus-progestin arm was stopped early in 2002 due to a small absolute increase in breast cancer risk: 38 vs. 30 cases per 10,000 person-years, an absolute excess of 8 cases per 10,000 women per year [8]. The estrogen-only arm (for women without a uterus) actually showed a decrease in breast cancer incidence (HR 0.77, 95% CI 0.59 to 1.01) over 7.2 years of follow-up [9].

The 2017 WHI cumulative 18-year follow-up, published in JAMA, found no increase in all-cause mortality for either the estrogen-only or estrogen-plus-progestin groups [10]. That finding reshaped professional guidance.

Current Guideline Consensus

The North American Menopause Society (NAMS) 2022 position statement, the Endocrine Society's 2022 guidelines, and ACOG's Practice Bulletin 141 all agree: for symptomatic women under age 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks [1][7][11]. The "timing hypothesis," validated by the ELITE trial (N=643), demonstrated that estradiol initiated within 6 years of menopause slowed carotid intima-media thickness progression, while estradiol initiated more than 10 years post-menopause did not [12].

What HRT Options Exist

Modern HRT bears little resemblance to the regimen tested in the WHI. Transdermal estradiol patches (delivering 0.025 to 0.1 mg/day) bypass first-pass liver metabolism and carry a lower venous thromboembolism (VTE) risk than oral formulations. A 2019 BMJ meta-analysis of over 500,000 women found no increased VTE risk with transdermal estrogen, compared to a roughly twofold increase with oral conjugated estrogens [13]. Micronized progesterone (100 to 200 mg nightly) has a more favorable breast safety profile than synthetic progestins like MPA, based on the E3N French cohort study (N=80,377) [14].

Symptoms Barrymore Has Described and Their Clinical Correlates

Barrymore's publicly described symptoms map onto well-characterized perimenopausal patterns. A clinical translation of her statements is useful for women who hear her words and wonder whether their own experience is similar.

Mood Instability and Irritability

Barrymore has described emotional reactivity that felt unfamiliar. The SWAN study documented that the odds of clinically significant depressive symptoms were 1.30 to 1.71 times higher during perimenopause compared to premenopause, even after adjusting for life stressors and history of depression [2]. Estradiol's role in serotonin receptor density and GABAergic signaling is well established. The 2019 Kronos Early Estrogen Prevention Study (KEEPS, N=727) found that oral conjugated equine estrogen improved mood scores on the PHQ-9 compared to placebo (p=0.02) [15].

Sleep Disruption

She has mentioned waking at 3 or 4 a.m. And being unable to return to sleep. Nocturnal awakenings are one of the most common perimenopausal complaints. A 2015 analysis from the Penn Ovarian Aging Study (N=255) found that 45.4% of perimenopausal women reported difficulty sleeping, compared to 31.3% of premenopausal controls [16]. Hot flashes that occur during sleep (night sweats) fragment sleep architecture, but sleep disruption also occurs independently of vasomotor symptoms, suggesting a direct CNS effect of fluctuating estradiol.

Cognitive Changes

Barrymore's references to "brain fog" are consistent with the subjective cognitive complaints reported by 44% to 62% of women during the menopausal transition, per a 2022 systematic review in Maturitas [17]. Objective testing in the SWAN cohort confirmed measurable declines in processing speed and verbal memory during perimenopause, with partial recovery in postmenopause.

Weight Fluctuation

She has discussed difficulty managing weight. Longitudinal SWAN data showed an average gain of 2.1 kg (4.6 lbs) over the menopausal transition, with a shift from gynoid to android fat distribution driven by declining estradiol and rising follicle-stimulating hormone (FSH) [18].

What Barrymore Has Not Said (and Why That Matters)

Responsible coverage requires noting what is absent from the public record. Barrymore has not confirmed using any specific form of HRT. She has not named estradiol, progesterone, testosterone, or any compounded formulation. She has not endorsed a telehealth platform, pharmacy, or brand.

Inference vs. Confirmation

Multiple wellness blogs and social media posts have attributed specific protocols to Barrymore. These attributions are unverified. HealthRX cannot confirm any HRT prescription or supplement regimen for this individual. The distinction between "she talked about perimenopause" and "she takes estradiol patches" is significant, and readers should be skeptical of sources that blur it.

The Compounding Pharmacy Question

Barrymore has expressed interest in "natural" approaches to hormonal health. The term "natural" in the context of HRT is imprecise. FDA-approved micronized progesterone (Prometrium) is derived from plant sources (yams or soy) and is biochemically identical to endogenous progesterone [19]. Compounded "bioidentical" hormones, while chemically identical, are not subject to the same FDA manufacturing oversight. NAMS and the Endocrine Society both recommend FDA-approved formulations over compounded products when an equivalent is available [1][7].

How This Coverage Fits the Broader Celebrity-HRT Conversation

Barrymore is part of a growing cohort of public figures who have discussed menopause and HRT since approximately 2019. Naomi Watts launched a menopause-focused brand. Halle Berry testified before the U.S. Congress in 2024 in support of menopause research funding. Michelle Obama described hot flashes in her memoir The Light We Carry (2022).

What Makes Barrymore's Contribution Distinct

Her talk show format allows extended, repeated conversations rather than a single disclosure. This format may produce a stronger sustained effect on audience behavior than a one-time interview. Her willingness to describe symptoms in granular, sometimes uncomfortable detail normalizes the specificity that patients need when reporting to clinicians. Vague complaints receive vague treatment. Specific symptom descriptions, such as "I wake at 3 a.m. And can't get back to sleep," lead to targeted interventions.

The Risk of Celebrity Health Influence

Dr. JoAnn Manson, Professor of Medicine at Harvard Medical School and a principal investigator of the WHI, has stated: "Celebrity disclosures can be a double-edged sword. They raise awareness, which is good, but they can also lead women to seek treatments that may not be appropriate for their individual risk profile" [20]. This caution applies to all celebrity health narratives, not specifically to Barrymore.

The American College of Obstetricians and Gynecologists (ACOG) recommends that "hormone therapy should be individualized based on the woman's symptoms, health history, and personal preferences, not based on media narratives" [11].

Clinical Takeaways for Women Inspired by Barrymore's Story

If Barrymore's openness has prompted you to consider whether your own symptoms warrant evaluation, the following steps are evidence-based.

Step 1: Symptom Documentation

Track symptoms for at least 2 to 4 weeks using a validated tool. The Menopause Rating Scale (MRS) or the Greene Climacteric Scale are both freely available and clinician-recognized.

Step 2: Laboratory Assessment

A baseline panel typically includes FSH, estradiol, thyroid function (TSH and free T4), CBC, and a metabolic panel. FSH levels above 25 mIU/mL on day 2 to 5 of the cycle suggest diminished ovarian reserve, though perimenopause is primarily a clinical diagnosis, not a laboratory one [1].

Step 3: Risk-Benefit Discussion

Bring your symptom log to your clinician and discuss whether HRT, non-hormonal options (SSRIs/SNRIs for vasomotor symptoms, cognitive behavioral therapy for insomnia), or a combination is appropriate. The 2023 Nonhormonal Management Position Statement from NAMS endorsed fezolinetant (Veozah), a neurokinin 3 receptor antagonist, as the first FDA-approved nonhormonal treatment for moderate-to-severe hot flashes, reducing frequency by 60% at 12 weeks in the SKYLIGHT 1 trial (N=500) [21].

Perimenopause screening at age 40 should include a conversation about contraception (perimenopausal women can still conceive), bone density baseline planning, and cardiovascular risk assessment per the ACC/AHA pooled cohort equations.